Sentences with phrase «new cell therapies»

The technology could help point to new cell therapies.

Scientists developing new cell therapy methods for the treatment of disorders such as sickle cell disease or leukemia need to consider how their culture conditions may affect the success of their translational research.

Not exact matches

Kite Pharma, one of the companies chasing a new generation of cancer drugs called chimeric antigen receptor T - cell (CAR - T) therapies, announced a patient death in a clinical trial of its experimental KTE - C19.

«The better we understand these cell types and how they affect disease, the better we will be able to develop new therapies to treat and cure disease.»

Basically, CAR - T therapy involves taking a patient's own immune «killer» T - cells, inserting new genetic code into those cells which turn them into cancer - hunters that can home in on malignant B - cells (another kind of immune cell), and then pumping these specialized leukemia - busting cells back into the patient.

On Wednesday, the U.S. Food and Drug Administration approved Novartis» Kymriah, the first drug for a new kind of cancer treatment called CAR - T cell therapy.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Cambridge, MA — February 6, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (OM).

Cambridge, MA — December 21, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it closed a $ 30 million Series C financing.

Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.

New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.

Risk Versus Reward: The Value of Cell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage developmCell Therapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develTherapy for Patients and Investors Source: Streetwise Reports (4/25/18) The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage developmcell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develtherapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage developmcell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage develtherapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

The startup describes itself as a deep data platform for the study of exosomes, which are small lipid vesicles — air - or fluid - filled cavities — that are excreted from cells and which deliver information that Mantra plans to use to come up with new drug therapies.

The cell therapy space, encompassing disruptive new treatment including stem cell therapy, immunotherapy and gene editing, has begun to mature, with a handful of product approvals and others in late - stage development.

February 2, 2017 By Ann Perry http://mbd.utoronto.ca/ When Arif Aziz learned last fall about a new independent study project that was bringing together MBA candidates and PhD students in health sciences and engineering to map the global market for stem cell therapies, he jumped at the opportunity.

He hopes Medicine by Design's collaboration with Rotman will help cultivate a new generation of bioscience entrepreneurs who will strengthen Toronto as a global hub for stem cell - based therapies and help Canada realize its full potential in the field.

For example, we've seen new discoveries in health care recently, especially in immuno - oncology therapies, which help the immune systems of cancer patients recognize and destroy cancerous cells.

«The event, the fourth of its kind, seeks to raise global awareness and create a forum for collaboration around the wide array of powerful and promising cell therapies, gene therapies, and immunotherapies emerging from medical institutions around the world, as well as the impact new technology will have on humanity and society,» a press release by the Cure Foundation explains (h / t Christian Post).

Researchers at the Center for Engineering MechanoBiology (CEMB), an NSF Science and Technology Center at the University of Pennsylvania, study plants like this Arabidopsis thaliana to learn how molecules, cells and tissues integrate mechanics within plant and animal biology, with the aim of creating new materials, biomedical therapies and agricultural technologies.

But as new methods of genetic modification emerge, both the scientific and the sports communities are becoming increasingly aware that gene therapy — the insertion of genes into an individual's cells and tissues — will make its way onto the playing field.

Unlike conventional chemotherapies and radiation that indiscriminately eradicate fast - growing tissues and ravage people's bodies with side effects, new therapies specifically target tumors using tailored cells from individual patients.

During the sessions, U.S. and Cuban scientists explored such topics as the molecular mechanisms cancer cells employ to evade the body's immune system, new tools to image and manipulate that system, and ways to rethink how such therapies can best be deployed to reach patients where they receive health services.

The new treatments, called CAR T cell therapies, eliminate cancer using people's own cells.

«In effort to treat rare blinding disease, researchers turn stem cells into blood vessels: Patients around the world contribute skin samples to test potential new therapy.»

«These findings stimulate new avenues for cell therapy approaches for regenerative medicine,» said Douglas Millay, PhD, study senior investigator and a scientist in the Division of Molecular Cardiovascular Biology at Cincinnati Children's.

However, centres in the US and Europe are already banking testicular tissue for boys in the hope that new stem - cell - based therapies will become available.

Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury.

A new study has identified a group of molecules in prostate - cancer cells that doctors might one day use to distinguish which patients should be treated with radiation therapy if rising PSA levels indicate their cancer has recurred after surgical removal of the prostate.

New treatments for spinal cord injury, including stem cells, gene therapy and electrical stimulation, are being studied.

«Cultural revolution in the study of the gut microbiome: Human gut - on - a-chip technology used to co-culture gut microbiome, human intestinal cells could lead to new therapies for inflammatory bowel diseases.»

Advocates of biomedical research, professional societies, and patient groups had mobilized to plead for a more careful review, warning that this bill's language was so vague it might hinder research on human stem cells and new medical therapies.

«Fibroblast growth factor receptor inhibitors are new therapies being developed in clinical trials for patients whose cancer cells have genetic alterations in this family of genes,» says Roychowdhury, a member of the OSUCCC — James Translational Therapeutics Program.

Furthermore, regulations stipulate that each new cell line generated be independently tested and validated for safety, making it impractical to develop patient - specific cells for therapies.

We believe that they will also lead to the development of a whole new range of therapies for neurodegenerative diseases of the central nervous system,» explains corresponding author of the study Jihwan Song, professor and director of Neural Regeneration and Therapy Group at the CHA Stem Cell Institute of CHA University.

The study «provided the surprising result that one new therapy currently being explored to lower insulin resistance promotes, rather than decreases, the formation of bone in mice,» says Darwin Prockop, a stem cell researcher at Texas A&M College of Medicine in Temple, who was not involved in the work.

A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis.

The goal of stem cell therapy is to replace the damaged tissue with new heart cells and restore the failing heart to normal function.

Tissue engineering provides a more practical means for researchers to study cell behavior, such as cancer cell resistance to therapy, and test new drugs or combinations of drugs to treat many diseases.

Inhibitory cell - based neuro - therapy is a new approach and has shown promise to date in early animal studies, warranting further development,» says Cory Nicholas, a co-first author.

A new therapy changes the balance of osteoblasts (pictured here) and fat cells in the bone marrow, leading to stronger bones.

Researchers, led by Joshua Mayourian at the Icahn School of Medicine at Mount Sinai, used mathematical modeling to simulate electrical interactions between these stem cells and heart cells to develop insight into possible adverse effects, as well as to hypothesize new methods for reducing some potential risks of this therapy.

Realistic stem cell therapies to replace diseased or damaged tissue may still be years away, but researchers have uncovered a promising new use for these undifferentiated cells: they can be programmed to become patient - specific laboratory models of inherited liver disease.

«Blood stem cells study could pave the way for new cancer therapy.»

«The results show we can now produce the number of cells needed for human therapy and get formation of new heart muscle on a scale that is relevant to improving the function of the human heart,» Laflamme said.

The findings — published today in Nature — provide significant insights into cell types fated to relapse and can help accelerate the quest for new, upfront therapies, says Dr. Dick, a Senior Scientist at Princess Margaret Cancer Centre, University Health Network, and Professor in the Department of Molecular Genetics, University of Toronto.

«Our study reveals a new mechanism that could be harnessed for biological therapies for lupus and other autoimmune diseases, where the immune system mistakenly targets the body's own cells,» says senior study author Boris Reizis, PhD, professor of Pathology and Medicine at NYU Langone.

New products and developments, such as new drugs for cancer, fresh therapies for rare diseases, progress in medications for HIV / AIDS, and advances in stem cell research had the greatest positive impaNew products and developments, such as new drugs for cancer, fresh therapies for rare diseases, progress in medications for HIV / AIDS, and advances in stem cell research had the greatest positive impanew drugs for cancer, fresh therapies for rare diseases, progress in medications for HIV / AIDS, and advances in stem cell research had the greatest positive impact.

The Mast Cells and Basophiles: Targets for Innovative Therapies project, funded by COST funding BM1007 of the EU, brings together European experts focusing on the identification of new target molecules for drug development, including allergy drugs.

To acquire new insights into the biology and possible therapy of these tumors, Feigin et al. looked for aberrant expression of G protein — coupled receptors, cell signaling proteins that have been successfully targeted for treatment of other disorders such as depression.

«Cancer therapies that attack the lipid composition of the cell membrane would be an entirely new class of anticancer drugs,» says co-senior study author Paul Beales, of the University of Leeds in the UK.